Biocon collaborates with Biomm to bring diabetes medication to the commercial market in Brazil.

Biocon, a leading biotechnology firm, has announced a partnership with Brazil-based Biomm SA for the commercialization of its diabetes drug in Brazil. This collaboration will involve Biocon handling the development, manufacturing, and supply of Semaglutide (gOzempic), while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market.

The CEO and MD of Biocon, Siddharth Mittal, expressed that this partnership is a significant step in their strategy to expand globally for Peptides beyond the US and Europe. He emphasized their focus on bringing complex GLP-1 drug-device combination products to market. This collaboration aims to provide advanced and high-quality treatment options to diabetes patients in Brazil.

Heraldo Marchezini, the CEO of Biomm, highlighted the importance of this partnership in Brazil, which has a high incidence of diabetes. With an estimated 21.5 million cases by 2030, the need for advanced treatments is crucial. The total addressable market opportunity for Semaglutide in Brazil is estimated to be around USD 580 million, according to IQVIA MAT data.

Brazil ranks fifth in the world for the highest incidence of diabetes, making this collaboration between Biocon and Biomm significant for improving access to advanced treatments and enhancing the quality of life for people living with diabetes in the country. The partnership between these two biotech firms is poised to make a positive impact on the healthcare landscape in Brazil.